| Size | Price | |
|---|---|---|
| 10mg | ||
| 25mg | ||
| 50mg | ||
| 100mg | ||
| 250mg |
Carperitide [SUN4936; SUN-4936; Atrial Natriuretic Peptide (ANP) (1-28), novel human, porcine] is an endogenous 28-amino acid hormone produced/ecreted by the human heart in response to cardiac injury and mechanical stretch. It has the potential to be used for the treatment of decompensated CHF (Congestive Heart Failure). Carperitide inhibits endothelin-1 secretion in a dose-dependent way. Carperitide is a hormone produced and secreted by the human heart.
| ln Vitro |
Carperitide is a diuretic, natriuretic, and vasodilatory peptide hormone that was first isolated from the mammalian heart. It is also known as atrial natriuretic peptide (ANP) (1-28), human, and porcine. Porcine ANP (1-28) inhibited immunoreactive endothelin-1 production in cultivated porcine endothelial cells, and this was accompanied by an increase in cellular cGMP levels after stimulation with angiotensin II (Ang II). After stimulation with Ang II, porcine ANP (1-28) significantly suppresses immunoreactive endothelin-1 production in the aorta [1]. ANP is a hormone found in the heart that regulates fluid and electrolyte balance. Using human umbilical vein endothelial cells in culture, angiotensin II (ANGII) and thrombin-stimulated endothelin-1 production are inhibited by ANP. Human umbilical vein endothelial cells' cyclic GMP is increased and immunoreactive (ir)-endothelin-1 production is inhibited by human ANP (1-28) [2]. Human 125I-ANP (1-28) has a mean equilibrium dissociation constant of 0.46 nM and binds to a single high-affinity receptor population in normal rat glomeruli. Human ANP (1-28) promotes the buildup of cGMP by binding with high affinity to glomerular ANP receptors. In normal rat glomeruli, human ANP (1-28) strongly increases the synthesis of cGMP but not cAMP [3].
|
|---|---|
| References |
[1]. Kohno M, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res. 1992 Feb;70(2):241-7.
[2]. Kohno M, et al. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest. 1991 Jun;87(6):1999-2004. [3]. Ballermann BJ, et al. Physiologic regulation of atrial natriuretic peptide receptors in rat renal glomeruli. J Clin Invest. 1985 Dec;76(6):2049-56. |
| Molecular Formula |
C127H203N45O39S3
|
|---|---|
| Molecular Weight |
3080.44381999999
|
| CAS # |
89213-87-6
|
| Related CAS # |
Carperitide acetate;1366000-58-9
|
| SMILES |
CC[C@@H]([C@H]1C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC2=CC=C(O)C=C2)=O)CCCNC(N)=N)=O)CC3=CC=CC=C3)=O)CO)=O)CC(N)=O)=O)CSSC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CO)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CO)=O)CO)=O)C(N[C@H](C(NCC(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1)=O)CCCNC(N)=N)=O)CC(O)=O)=O)CCSC)=O)CCCNC(N)=N)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)CC(C)C)=O)=O)CO)=O)CCC(N)=O)=O)C)=O)=O)C
|
| Synonyms |
SUN-4936; ANP (1-28); alpha-Atriopeptin; SUN4936; SUN 4936
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3246 mL | 1.6231 mL | 3.2463 mL | |
| 5 mM | 0.0649 mL | 0.3246 mL | 0.6493 mL | |
| 10 mM | 0.0325 mL | 0.1623 mL | 0.3246 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
